Form 4: LeMaitre Vascular CEO George W. LeMaitre Reports Acquisition of Dividend Equivalent Rights
SEC Form 4 Filing
George W. LeMaitre, Chairman and CEO of LeMaitre Vascular, acquired dividend equivalent rights related to previously granted restricted stock units and performance share units.
Summary
- George W. LeMaitre, the Chairman and CEO of LeMaitre Vascular, has reported the acquisition of dividend equivalent rights.
- These rights are associated with previously granted restricted stock unit (RSU) and performance share unit (PSU) awards.
- The dividend equivalent rights vest proportionately with the underlying RSU and PSU awards.
- A total of 29.6303 dividend equivalent rights were acquired on December 5, 2024.
- Each dividend equivalent right is equivalent to one share of LeMaitre Vascular's common stock.
Sentiment
Score: 7
Explanation: The document is a routine disclosure of insider transactions, which is generally neutral. The acquisition of dividend equivalent rights is a positive sign of alignment between management and shareholders, but it is not a major event.
Positives
- The acquisition of dividend equivalent rights indicates continued alignment of the CEO's interests with those of shareholders.
- The vesting schedule of the rights is tied to the vesting of the underlying stock awards, promoting long-term value creation.
Industry Context
This filing is a routine disclosure of insider transactions, which is common for publicly traded companies. It reflects the ongoing compensation practices of LeMaitre Vascular.
Comparison to Industry Standards
- The use of dividend equivalent rights is a common practice in executive compensation packages, particularly for companies that issue stock-based awards.
- Many companies in the medical device industry, such as Medtronic and Boston Scientific, use similar mechanisms to align executive interests with shareholder value.
- The vesting schedules tied to the underlying stock awards are also standard practice, encouraging long-term performance.
Stakeholder Impact
- The acquisition of dividend equivalent rights has a minor positive impact on shareholders by aligning management's interests with the company's performance.
Key Dates
| Date | Description |
|---|---|
| 12/20/2019 | Date of grant for the restricted stock unit award associated with the first set of dividend equivalent rights. |
| 12/02/2020 | Date of grant for the restricted stock unit award associated with the second set of dividend equivalent rights. |
| 12/11/2021 | Date of grant for the restricted stock unit award associated with the third set of dividend equivalent rights. |
| 12/12/2022 | Date of grant for the restricted stock unit award associated with the fourth and fifth set of dividend equivalent rights. |
| 12/08/2023 | Date of grant for the restricted stock unit award associated with the sixth set of dividend equivalent rights. |
| 12/05/2024 | Date of acquisition of the dividend equivalent rights. |
| 12/09/2024 | Date of filing of the SEC Form 4. |
Keywords
dividend equivalent rights, restricted stock units, performance share units, insider trading, executive compensation, LMAT, LeMaitre Vascular, George W. LeMaitre
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.